Cingulate Advances ADHD Treatment Toward 2026 Commercial Launch Following FDA NDA Acceptance

Stonegate Capital Partners has updated its coverage of Cingulate Inc. (NASDAQ: CING), highlighting the company's continued progress in transforming CTx-1301 into a commercial ADHD franchise. The third quarter of 2025 saw Cingulate achieve several critical milestones, including FDA acceptance of the CTx-1301 New Drug Application with a Prescription Drug User Fee Act target action date of May 31, 2026. This regulatory advancement positions the company for a potential 2026 launch, subject to FDA approval, in the substantial U.S. ADHD market.

The NDA submission follows a defined regulatory path under the 505(b)(2) pathway and includes comprehensive adult and pediatric Phase 3 data. The clinical results demonstrate rapid onset and full-day symptom control with a safety profile consistent with existing long-acting methylphenidate products. Cingulate's receipt of a small-business PDUFA fee waiver provides additional capital preservation as the company prepares for potential approval and commercial launch. The company's proprietary Precision Timed Release platform technology enables CTx-1301 to deliver three timed releases of dexmethylphenidate in a single daily tablet designed to address the entire active day for ADHD patients.

Cingulate's pipeline extends beyond CTx-1301, with CTx-1302 advancing toward development for patients who respond better to amphetamine-based stimulants and CTx-2103 progressing for anxiety disorders. These programs demonstrate the scalability of the PTR platform across multiple neuropsychiatric indications and support the company's broader strategic vision. The execution of an exclusive commercial supply agreement with Bend Bio Sciences secures U.S. manufacturing capacity ahead of potential launch, addressing a critical component of the commercialization strategy.

Financially, Cingulate reported $6.1 million in cash and cash equivalents and approximately $1.6 million in working capital as of the third quarter 2025. Research and development expenses increased to $2.8 million from $1.4 million year-over-year, while general and administrative expenses rose to $3.1 million from $1.9 million, reflecting investments in Phase 3 activities, NDA support, and commercial planning. The net loss widened to $7.3 million compared to $4.1 million in the third quarter of 2024, with $13.6 million of net cash used in operations during the first nine months of 2025. Post-quarter-end, a $6.0 million unsecured promissory note extended the company's cash runway into the second quarter of 2026.

Management enhancements include the appointment of industry veteran Bryan Downey as Chief Commercial Officer, bringing more than 25 years of commercial experience to lead launch preparation and go-to-market strategy. Downey will oversee execution of the partnership with Indegene, including market access, omnichannel engagement, and field deployment ahead of potential 2026 approval. Jennifer Callahan continues as Interim CEO and CFO alongside Executive Chairman Jay Roberts, providing leadership continuity through the FDA review process. Stonegate Capital Partners' valuation analysis using a discounted cash flow model returns a range of $15.29 to $31.44 with a midpoint of $21.86, reflecting the potential value creation from successful commercialization of CTx-1301.